Verici Dx PLC Result of AGM
25 June 2024 - 10:27PM
RNS Regulatory News
RNS Number : 8191T
Verici Dx PLC
25 June 2024
Verici Dx
plc
("Verici Dx" or the
"Company")
Result of AGM and voting
results
Verici Dx plc (AIM: VRCI), a
developer of advanced clinical diagnostics for organ
transplant, announces that at the Annual General Meeting
("AGM") held earlier today, all resolutions were duly
passed.
The voting results of the AGM were
as follows:
|
|
In Favour
|
Against
|
Withheld
|
|
Resolution
|
Votes
|
%
|
Votes
|
%
|
Votes
|
|
1
|
109,919,167
|
97.96
|
2,287,678
|
2.04
|
76
|
|
2
|
112,096,318
|
99.90
|
110,603
|
0.10
|
0
|
|
3
|
112,205,310
|
99.99
|
1,611
|
0.01
|
0
|
|
4
|
112,081,736
|
99.89
|
125,185
|
0.11
|
0
|
|
5
|
112,085,956
|
99.89
|
120,965
|
0.11
|
0
|
|
6
|
111,792,090
|
99.63
|
414,740
|
0.37
|
91
|
|
7
|
112,203,528
|
99.99
|
3,233
|
0.01
|
160
|
|
8
|
112,192,472
|
99.99
|
14,289
|
0.01
|
160
|
|
9
|
112,154,800
|
99.95
|
51,921
|
0.05
|
200
|
Enquiries:
|
Verici Dx
|
www.vericidx.com
|
|
Sara Barrington, CEO
|
investors@vericidx.com
|
|
Julian Baines, Chairman
|
|
|
|
|
|
|
|
|
Singer Capital Markets (Nominated Adviser &
Broker)
|
Tel: +44 20 7496
3000
|
|
Aubrey Powell / Sam
Butcher
|
|
|
|
|
About Verici Dx plc www.vericidx.com
Verici Dx is a developer of a
complementary suite of leading-edge tests forming a kidney
transplant platform for personalised patient and organ response
risk to assist clinicians in medical management for improved
patient outcomes. The underlying technology is based upon
artificial intelligence assisted transcriptomic analysis to provide
RNA signatures focused upon the immune response and other
biological pathway signals critical for transplant prognosis of
risk of injury, rejection and graft failure from pre-transplant to
late stage. The Company also has a mission to accelerate the pace
of innovation by research using the fully characterised data from
the underlying technology, including through collaboration with
medical device, biopharmaceutical and data science
partners.
The foundational research was driven
by a deep understanding of cell-mediated immunity and is enabled by
access to expertly curated collaborative studies in highly
informative cohorts in kidney transplant.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
RAGBDGDLRDDDGSU
Verici Dx (LSE:VRCI)
Historical Stock Chart
From Nov 2024 to Dec 2024
Verici Dx (LSE:VRCI)
Historical Stock Chart
From Dec 2023 to Dec 2024
